PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Cardiology, University Hospitals of Geneva Department of Medical Specializations, Geneva, Switzerland.\', \'Department of Health and Community Medicine, University of Geneva, Geneva, Switzerland.\', \'Intensive Care Division, Department of Acute Medicine, University Hospitals of Geneva, Oakland, California, USA.\', \'Department of Internal Medicine, University Hospitals of Geneva, Geneva, Switzerland.\', \'Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Clinical Pharmacology, Intensive Care and Emergency Medicine, University Hospitals of Geneva, Geneva, Switzerland.\', \'Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.\', \'Department of Cardiology, University Hospitals of Geneva Department of Medical Specializations, Geneva, Switzerland Francois.Mach@hcuge.ch.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • e00152610.1136/openhrt-2020-001526
?:hasPublicationType
?:journal
  • Open heart
is ?:pmid of
?:pmid
?:pmid
  • 33833064
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.281
?:rankingScore_hIndex
  • 15
?:title
  • Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all